OncoImmune

United States
Barbourmeade, Kentucky, United States, 20852

Company profile

OncoImmune company profile

OncoImmune is a clinical-stage biopharmaceutical company that engages in the discovery and development of biopharmaceuticals for the treatment of cancer and autoimmune disease. It has completed a Phase II clinical trial of CD24Fc for the prophylactic treatment of acute Graft versus Host Disease for leukemia patients undergoing hematopoietic stem cell transplantation and is poised to launch a pivotal trial for the indication. Oncolmmune was founded in 2000 and is based in Rockville, Maryland.

Business identity

Contact email
[email protected]
Phone number
(301)557-9119
Operating status
Closed
Company type
For Profit
Employee range
10,001+ employees
Revenue range
$10M+
Founded
2000-01-01, Year

Headquarters

Postal code
20852
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
3
Total equity funding
$74M
Last funding
Series B / $56M / 2020-09-09
Last equity funding
Series B / $56M
Investors
5
Lead investors
2
Founders
4
Articles
54
Exited on
2020-11-23

Founders and investors

Founders

Kun-Liang GuanMing YouPan ZhengYang Liu

Lead investors

3E BioventuresHuimei Capital

Investors

3E BioventuresGBA FundGF Xinde Investment ManagementHuimei CapitalKaitai Capital